{"id":533655,"date":"2021-09-02T07:04:12","date_gmt":"2021-09-02T11:04:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/"},"modified":"2021-09-02T07:04:12","modified_gmt":"2021-09-02T11:04:12","slug":"prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/","title":{"rendered":"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WILMINGTON, Del., Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Morgan Stanley 19<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Global Healthcare Conference<br \/><\/strong>Fireside chat at 11:45 a.m. ET on Thursday, September 9, 2021<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>H.C. Wainwright 23<\/strong><br \/>\n          <sup><br \/>\n            <strong>rd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Global Investment Conference<br \/><\/strong>Corporate presentation at 7:00 a.m. ET on Monday, September 13, 2021<\/li>\n<\/ul>\n<p align=\"justify\">A live webcast of the Morgan Stanley fireside chat and H.C. Wainwright presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investor Section of the Company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zd6ATYxnsbIte6dJCXWiG7zmi787u3_bCtrWh81F1WlehGyeoIxOI6soZysc9zPfXtRX6NHT-zT8TLe4S8vC83-jZbsM-If6XNwXmA5VnfEsDucu5uUJrmuw_sF8MyC1BCtyY_B7i3zFHwXKp6sRlo7ScmCRT1fLprwj8RXh00ECzlw02lO5uINjQQUhEFHfh8Fvj6BUyIWuR2XXU-FjXuJar1H1QLiuNUQlkAC_mLQ=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.preludetx.com\/news-and-events\/events-and-presentations<\/a>, where a replay of the events will also be available for a limited time.<\/p>\n<p align=\"justify\">\n        <strong>About Prelude Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company\u2019s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude\u2019s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company\u2019s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed\/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.<\/p>\n<p>\n        <strong>Investor Contact:<br \/><\/strong>Stacey Jurchison<br \/>Executive Director, Corporate Affairs<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XJ-js88L-uxXMCJxCWaVmXVwaaUuZWtDwbytCmqU1dhckCq9EpVRyh78s58aSzMnnpSPraRQEOps5FHVgbF4AlGG7yvnMEcSNK7HCUq7pz8=\" rel=\"nofollow noopener\" target=\"_blank\">sjurchison@preludetx.com<\/a><\/p>\n<p align=\"justify\">Melissa Forst<br \/>Argot Partners<br \/>212.600.1902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nP1I8Z9MJFKiog6U4k5BLOSvz07JBufSL_rZZvE1P60g0lHJt141vPL0i-ln0BAguYg621C3upVgPXgSIq_x5elK-gEzj1J0Uzm0mpxQdwU=\" rel=\"nofollow noopener\" target=\"_blank\">prelude@argotpartners.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<br \/><\/strong>Deborah Elson<br \/>Argot Partners<br \/>212.600.1902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nP1I8Z9MJFKiog6U4k5BLOSvz07JBufSL_rZZvE1P61Cgum6qo7C-gBa7W2nEXQP6p7dJ6eOLTib6g7sGN_M0BEXOvEFCWoVkb634vYkd44=\" rel=\"nofollow noopener\" target=\"_blank\">prelude@argotpartners.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjUxYjZkMDQtOTA2OS00YjYwLWE3YmQtZDRjMmZlNjMxZjdjLTEyMTM4NzY=\/tiny\/Prelude-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19 th Annual Global Healthcare ConferenceFireside chat at 11:45 a.m. ET on Thursday, September 9, 2021 H.C. Wainwright 23 rd Annual Global Investment ConferenceCorporate presentation at 7:00 a.m. ET on Monday, September 13, 2021 A live webcast of the Morgan Stanley fireside chat and H.C. Wainwright presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investor Section of the Company\u2019s website, https:\/\/investors.preludetx.com\/news-and-events\/events-and-presentations, where a replay of the events will also be available for a limited time. About Prelude Therapeutics Prelude Therapeutics is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-533655","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19 th Annual Global Healthcare ConferenceFireside chat at 11:45 a.m. ET on Thursday, September 9, 2021 H.C. Wainwright 23 rd Annual Global Investment ConferenceCorporate presentation at 7:00 a.m. ET on Monday, September 13, 2021 A live webcast of the Morgan Stanley fireside chat and H.C. Wainwright presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investor Section of the Company\u2019s website, https:\/\/investors.preludetx.com\/news-and-events\/events-and-presentations, where a replay of the events will also be available for a limited time. About Prelude Therapeutics Prelude Therapeutics is a &hellip; Continue reading &quot;Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T11:04:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences\",\"datePublished\":\"2021-09-02T11:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/\",\"name\":\"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=\",\"datePublished\":\"2021-09-02T11:04:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences - Market Newsdesk","og_description":"WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19 th Annual Global Healthcare ConferenceFireside chat at 11:45 a.m. ET on Thursday, September 9, 2021 H.C. Wainwright 23 rd Annual Global Investment ConferenceCorporate presentation at 7:00 a.m. ET on Monday, September 13, 2021 A live webcast of the Morgan Stanley fireside chat and H.C. Wainwright presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investor Section of the Company\u2019s website, https:\/\/investors.preludetx.com\/news-and-events\/events-and-presentations, where a replay of the events will also be available for a limited time. About Prelude Therapeutics Prelude Therapeutics is a &hellip; Continue reading \"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T11:04:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences","datePublished":"2021-09-02T11:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/"},"wordCount":270,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/","name":"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=","datePublished":"2021-09-02T11:04:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE2MSM0Mzg2MTY0IzIyMDIzMjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-two-upcoming-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=533655"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533655\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=533655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=533655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=533655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}